Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
- Transaction values animal health therapeutics pioneer at up to $520 million
- Novo Holdings co-led Invetx Series B financing round in 2022
Boston, MA, July 18, 2024 – Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio company, Invetx, has agreed to be acquired by Dechra Pharmaceuticals Limited (“Dechra”), an international veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis.
